Glenmark India formulations

Glenmark Pharmaceuticals Q3 FY26 Revenue Rises 15.1% on Strong Domestic and North American Growth

6 hours ago

Glenmark Pharmaceuticals Ltd. (NSE: GLENMARK) reported consolidated revenue of ₹39,006 million for the third quarter ended December 31, 2025, a…